Thea D' Ambrosio

Array ( [id] => 18887707 [patent_doc_number] => 11866468 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Methods for treatment of nephrotic syndrome and related conditions [patent_app_type] => utility [patent_app_number] => 16/036643 [patent_app_country] => US [patent_app_date] => 2018-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 32 [patent_no_of_words] => 27172 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16036643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828333 [patent_doc_number] => 20200129448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => COMPOSITIONS AND METHODS FOR WOUND CLOSURE [patent_app_type] => utility [patent_app_number] => 16/630384 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13392 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187540 [patent_doc_number] => 11578109 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers [patent_app_type] => utility [patent_app_number] => 16/626458 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 30477 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16680753 [patent_doc_number] => 10940209 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-09 [patent_title] => Glycotargeting therapeutics [patent_app_type] => utility [patent_app_number] => 16/028209 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 40299 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16028209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519527 [patent_doc_number] => 20180311306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => METHODS FOR TREATING HYPOTENSION [patent_app_type] => utility [patent_app_number] => 16/016088 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16016088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16519469 [patent_doc_number] => 10870679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-22 [patent_title] => Modulation of structured polypeptide specificity [patent_app_type] => utility [patent_app_number] => 16/013795 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 33 [patent_no_of_words] => 28097 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16013795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336053 [patent_doc_number] => 20220002384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => FIBRONECTIN BINDING DOMAIN CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/623225 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16623225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283758 [patent_doc_number] => 20200277360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => C3B INACTIVATING POLYPEPTIDE [patent_app_type] => utility [patent_app_number] => 16/620383 [patent_app_country] => US [patent_app_date] => 2018-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16620383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710427 [patent_doc_number] => 20210077574 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => PHYCOCYANIN COMPOSITION FOR USE IN INHIBITING BONE RESORPTION [patent_app_type] => utility [patent_app_number] => 16/620287 [patent_app_country] => US [patent_app_date] => 2018-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16620287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15796955 [patent_doc_number] => 20200121620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => SENOLYTIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/616251 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618485 [patent_doc_number] => 20180360794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS [patent_app_type] => utility [patent_app_number] => 15/986668 [patent_app_country] => US [patent_app_date] => 2018-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15986668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618483 [patent_doc_number] => 20180360793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS [patent_app_type] => utility [patent_app_number] => 15/986665 [patent_app_country] => US [patent_app_date] => 2018-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15986665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18399330 [patent_doc_number] => 11661456 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-30 [patent_title] => Sialylated glycoproteins [patent_app_type] => utility [patent_app_number] => 15/985288 [patent_app_country] => US [patent_app_date] => 2018-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 16068 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15985288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16093547 [patent_doc_number] => 20200200760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => COMPOSITIONS COMPRISING LIGANDS TO RHOB PROTEIN AND THE USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/613299 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11159 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17266402 [patent_doc_number] => 11191806 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Polymyxin-based pharmaceutical composition for treating infectious diseases [patent_app_type] => utility [patent_app_number] => 16/955896 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13880 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17587689 [patent_doc_number] => 11325945 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Peptide based PCSK9 vaccine [patent_app_type] => utility [patent_app_number] => 16/498084 [patent_app_country] => US [patent_app_date] => 2018-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9407 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13489827 [patent_doc_number] => 20180296456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => Decapeptide-12 Modulation of Sirtuin Gene Expression in Epidermal Keratinocyte Progenitors [patent_app_type] => utility [patent_app_number] => 15/941753 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15941753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866185 [patent_doc_number] => 20200140496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => METHOD FOR PREPARING A LIQUID EXTRACT OF PHYCOBILIPROTEINS, IN PARTICULAR PHYCOCYANIN, FROM CYANOBACTERIA OR MICROALGAE AND EXTRACT THUS OBTAINED [patent_app_type] => utility [patent_app_number] => 16/496725 [patent_app_country] => US [patent_app_date] => 2018-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3550 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440887 [patent_doc_number] => 20180271986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => GLYCOTARGETING THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 15/925628 [patent_app_country] => US [patent_app_date] => 2018-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15925628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410255 [patent_doc_number] => 20180256670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => TREATMENT OF ENDOMETRIOSIS, ANGIOGENESIS AND/OR ENDOMETRIAL LESION GROWTH [patent_app_type] => utility [patent_app_number] => 15/924964 [patent_app_country] => US [patent_app_date] => 2018-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15924964 [rel_patent_id] =>[rel_patent_doc_number] =>)